Dynavax Technologies (NASDAQ:DVAX) Price Target Raised to $31.00 at HC Wainwright

Dynavax Technologies (NASDAQ:DVAX) had its target price raised by HC Wainwright from $29.00 to $31.00 in a report released on Tuesday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX opened at $12.48 on Tuesday. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The stock has a market cap of $1.64 billion, a PE ratio of 96.01 and a beta of 1.34. The company’s fifty day moving average is $12.76 and its 200 day moving average is $11.65. Dynavax Technologies has a 52 week low of $9.74 and a 52 week high of $14.41.

Institutional Investors Weigh In On Dynavax Technologies

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nordea Investment Management AB increased its stake in shares of Dynavax Technologies by 42.7% in the fourth quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock worth $10,034,000 after buying an additional 232,690 shares during the period. GAMMA Investing LLC grew its holdings in Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 1,457 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Dynavax Technologies by 5.7% in the third quarter. Franklin Resources Inc. now owns 82,415 shares of the biopharmaceutical company’s stock valued at $862,000 after acquiring an additional 4,459 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of Dynavax Technologies during the third quarter valued at about $89,000. Finally, Sanctuary Advisors LLC boosted its holdings in shares of Dynavax Technologies by 9.1% during the third quarter. Sanctuary Advisors LLC now owns 17,727 shares of the biopharmaceutical company’s stock worth $197,000 after purchasing an additional 1,484 shares during the period. Institutional investors own 96.96% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.